Found 8 articles for: "GLP-1"
GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa
February 2026 | Volume 25 | Issue 2 | Features | 178 | Copyright © February 2026
Prevalence of Pruritus in Type 2 Diabetic Patients on GLP-1 Agonist Therapy
January 2026 | Volume 25 | Issue 1 | Editorials | e24 | Copyright © January 2026
Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024
January 2026 | Volume 25 | Issue 1 | Original Article | 11 | Copyright © January 2026
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for conditions beyond type 2 diabetes, including psoriasis and hidradenitis suppurat...
Read MoreGLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities
December 2025 | Volume 24 | Issue 12 | Original Article | 1174 | Copyright © December 2025
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with many comorbidities, including obesity, diabetes, cardiovascular risk factors, me...
Read MoreGlucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study
September 2025 | Volume 24 | Issue 9 | Original Article | 869 | Copyright © September 2025
Background: Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor ag...
Read MoreConsiderations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin
June 2025 | Volume 24 | Issue 6 | Editorials | 638 | Copyright © June 2025
A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies
April 2025 | Volume 24 | Issue 4 | Features | 413 | Copyright © April 2025
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack o...
Read MoreCross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists
September 2024 | Volume 23 | Issue 9 | Editorials | e181 | Copyright © September 2024
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
